Mr To, aged 68, has been a Director since 2000 and an Executive Director and Chairman of the Company since 2006. He is also the Chairman of the Nomination Committee and a member of the Remuneration Committee and Technical Committee of the Company. He is managing director of Hutchison Whampoa (China) Limited (“Hutchison China”) and has been with Hutchison China for over 39 years, building its business from a small trading company to a multi-billion dollar investment group. He has negotiated major transactions with multinationals such as Procter & Gamble (“P&G”), Lockheed, Pirelli, Beiersdorf, United Airlines and British Airways. He is currently the chairman of Gama Aviation Plc and formerly served as independent non-executive director on the boards of China Southern Airlines Company Limited and Air China Limited.
Mr To’s career in China spans more than 44 years. He is the original founder of the China healthcare business of Hutchison Whampoa Limited (“HWL”) (currently a subsidiary of CK Hutchison Holdings Limited (“CKHH”)) and has been instrumental in the acquisitions made to date. He received a Bachelor’s Degree in Mechanical Engineering from Imperial College, London and a Master in Business Administration from Stanford University’s Graduate School of Business.
Mr Hogg, aged 54, has been the Chief Executive Officer and an Executive Director of the Company since 2006. He is also a member of the Nomination
Committee and Technical Committee of the Company. He joined the business in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the Company’s strategy, business and listings. This includes the establishment of the Innovation Platform, Hutchison MediPharma, which now comprises eight drug candidates that are being investigated in clinical studies around the world and a scientific team of about 500 people. Furthermore, Mr Hogg oversaw the acquisition and operational integration of assets led to the formation of the Company’s Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Prior to joining the Company, Mr Hogg spent ten years with P&G, starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business, followed by a move to Brussels to run P&G’s global bleach business.
Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and a Master in Business Administration from the University of Tennessee.
Mr Cheng, aged 53, has been an Executive Director since 2011 and Chief Financial Officer of the Company since 2008. He is also a member of the
Nomination Committee of the Company.
Prior to joining the Company, Mr Cheng was Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American
Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of Chartered Accountants Australia and New Zealand.
Dr Su, aged 62, has been an Executive Director of the Company since 2017. He is also a member of the Nomination Committee and Technical Committee of the Company. He has been the Executive Vice President and Chief Scientific Officer of the Company since 2012. Dr Su has headed all drug discovery and research since he joined the Company, including master-minding the Company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in the Company’s product pipeline. Prior to joining the Company in 2005, Dr Su spent 15 years with the U.S. Research and Development Department of Pfizer, Inc. with his last position as director of the Medicinal Chemistry Department.
In March 2017, Dr Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai. He completed a PhD and Post-doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Dr Eldar, aged 66, has been a Non-executive Director of the Company since 2016. He is also a member of the Nomination Committee of the Company. He has more than 30 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd which focuses on large scale projects including desalination, wastewater treatment and water reuse. He was formerly an independent non-executive director of Leumi Card Ltd., a subsidiary of Bank Leumi Le-Israel B.M., one of
Israel’s leading credit card companies.
Dr Eldar holds a Doctor of Philosophy degree in Government from Harvard University, Master of Arts degree in Government from Harvard University, Master of Arts degree in Political Science and Public Administration from the Hebrew University of Jerusalem and a Bachelor of Arts degree in Political Science from the Hebrew University of Jerusalem.
Ms Shih, aged 68, has been a Non-executive Director and Company Secretary of the Company since 2006, Nomination Committee member since April 2019 and company secretary of Group companies since 2000. She is also an executive director and company secretary of CKHH. She has been with the Cheung Kong (Holdings) Limited (“CKH”) group since 1989 and with HWL from 1991 to 2015. Both CKH and HWL became wholly-owned subsidiaries of CKHH in 2015. She has acted in various capacities within the HWL group, including head group general counsel and company secretary of HWL and director and company secretary of HWL subsidiaries and associated companies. Ms Shih is a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited and Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust. She is also a member of Board of Commissioners of PT Duta Intidaya Tbk.
She has over 35 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is currently the International President and Executive Committee Chairman of The Chartered Governance Institute (“CGI”, formerly The Institute of Chartered Secretaries and Administrators) and a past President and current chairperson of certain committees and panels of The Hong Kong Institute of Chartered Secretaries (“HKICS”).
Ms Shih received a Bachelor of Science degree in Education and a Master of Arts degree from the University of the Philippines and a Master of Arts degree and a Master of Education degree from Columbia University, New York. Ms Shih is a solicitor qualified in England and Wales, Hong Kong and Victoria, Australia and a Fellow of both the CGI and HKICS, holding Chartered Secretary and Chartered Governance Professional dual designations.
Mr Carter, aged 59, has been the Senior Independent Non-executive Director of the Company since 2017. He is also Chairman of the Remuneration Committee and a member of the Audit Committee, Nomination Committee and Technical Committee of the Company. He has more than 25 years of experience in the pharmaceutical industry. From 2006 to 2016, Mr Carter served in various senior executive roles at Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company, with the last position as Executive Vice President, Commercial Operations. In this role, Mr Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of Gilead’s products. Prior to joining Gilead, he spent 14 years with GlaxoSmithKline PLC (GSK) and its group companies, with the last position as Regional Head of the International Business in Asia. He is currently director of Mallinckrodt plc. He was formerly a director of Alder Biopharmaceuticals, Inc.
Mr Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the Chartered Institute of Management Accountants in the United Kingdom.
Dr Ferrante, aged 62, has been an Independent Non-executive Director of the Company since 2017. She is also the Chairman of the Technical Committee and a member of the Audit Committee and Nomination Committee of the Company. She has more than 25 years of experience in the pharmaceutical industry. She was the former Chief Medical Officer and Head of Research and Development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. From September 2007 to July 2013, Dr Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area and Cambridge USA Site Head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer, Inc., with the last position as Vice President, Oncology Development. Dr Ferrante is currently a member of the board of directors of Progenics Pharmaceuticals, Inc., MacroGenics, Inc and Unum Therapeutics Inc. She was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016.
Dr Ferrante has been an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr Ferrante holds a Bachelor of Science degree in Chemistry and Biology from Providence College and a Doctor of Medicine from Georgetown University.
Mr Jack, aged 69, has been an Independent Non-executive Director of the Company since 2017. He is also the Chairman of the Audit Committee and a member of the Nomination Committee and Remuneration Committee of the Company. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets), Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals) and of COSCO SHIPPING Development Co., Ltd., formerly known as “China Shipping Container Lines Company Limited” (an integrated financial services platform principally engaged in vessel and container leasing).
He holds a Bachelor of Commerce degree from The University of New South Wales, Australia and is a Fellow of the Hong Kong Institute of Certified Public Accountants and an Associate of Chartered Accountants Australia and New Zealand.
Professor Mok, aged 59, has been an Independent Non-executive Director of the Company since 2017. He is also a member of the Nomination Committee and Technical Committee of the Company. He has more than 30 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation Named Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. He has contributed to over 200 articles in international peer-reviewed journals, as well as multiple editorials and textbooks.
In October 2018, Professor Mok was the first Chinese to be bestowed with the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, one of the most prestigious international honours and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide.
Professor Mok is a Non-executive Director of AstraZeneca PLC, a board director of the American Society of Clinical Oncology (“ASCO”) and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO). He is also Past President of International Association for the Study of Lung Cancer (IASLC).
Professor Mok is also closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People’s Hospital, Guest Professorship at Peking University School of Oncology and Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University.
Professor Mok received his Bachelor of Medical Science degree and Doctor of Medicine from University of Alberta, Canada. He is also a Fellow of Royal College of Physicians and Surgeons of Canada, Hong Kong College of Physicians, Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh and ASCO.